While there was little in wide-moat BlackRock's fourth-quarter earnings to alter our long-term view of the firm, we expect to increase our fair value estimate to around $750 per share from $620 to account for the continued recovery in the equity, credit and currency markets following the steep COVID-19 induced sell off in the first quarter of 2020.
After updating our model for the increased purchase price, we are maintaining our $48 fair value estimate for Cisco.
New CEO Pat Gelsinger has a rich technology background, having served as CEO of VMware since 2012.
We are maintaining our fair value estimate of the narrow-moat company and view the shares as undervalued.
We reiterate our view that the delisting of the ADS will have negligible impact on the companies' operations or underlying value.
Despite the rally, actual economic exposure differs widely.
Our fair value estimate for narrow-moat Qualcomm remains $124 per share.
We expect robust year-over-year growth in 2021 against a soft comparable followed by more tepid growth in 2022.
We think the market has valued Stellantis as though fundamentals will only deteriorate from historic levels.
We raise our fair value estimate for the wide-moat company.
We believe the wide-moat firm is trading above its $107 fair value estimate.
We believe the breach will benefit vendors within our security coverage.
States are demanding Google redesign its search results, as they claim the firm itself benefits based on which results are prioritized.
We see a strong strategic rationale for the combined company, which will keep the Tilray name.
We anticipate that the Federal Open Market Committee will be in a holding pattern for some time, with the meetings and releases likely to be relatively mundane for a while.
The wide-moat firm continues to show significant innovation. We plan to increase our fair value estimate.
The FDA provided emergency use authorization, or EUA, for Pfizer and partner BioNTech’s COVID-19 vaccine BNT162b2 on Dec. 11. However, we are not changing our fair value for either Pfizer or BioNTech as the EUA was largely expected.
We are raising our fair value estimate to $140 from $127 due to much higher subscriber growth offset slightly by higher content spending.
Wide-moat Adobe reported strong fourth-quarter results, including upside to consensus for both revenue and non-GAAP EPS, and provided quarterly guidance that was ahead of Street expectations
At today's prices, resist booking an investment in this advantaged travel operator.
Despite the Federal Trade Commission and 47 states filing separate antitrust suits, we are maintaining our FVE.
The company's recent resilience has demonstrated its agility and understanding of its customers.
We're raising the technology firm's fair value estimate to $61 per share.
We believe Warner Bros. studio's announcement to release its entire 2021 movie slate simultaneously in movie theaters and on HBO Max is a reasonable response to the pandemic.
We're raising Waddell & Reed's fair value estimate to $25 per share.
We were not too surprised when the no-moat firm was acquired.
Meanwhile, wide-moat Salesforce reported strong results, including meaningful upside to both revenue and non-GAAP EPS, while guidance for the fourth quarter was mixed.
We are maintaining our fair value estimate of $253 for Salesforce as good organic results are offset by the seemingly modest deleterious impact on shareholder value arising from the Slack acquisition.
We view the acquisition as a necessary strategic move that could strengthen Uber’s overall network effect moat source.
The firm's near-term outlook looks slightly higher than our expectations.
We see a long runway for growth as the company gains traction with Zoom Phone and evolves its main application to a communication platform.
The acquisition should deliver a modest premium to IHS Markit shareholders.
With consistency that we rarely see in medical technology, Stryker has delivered another quarter of strong growth across all three of its segments.
Nasdaq recently announced the acquisition of Verafin, an anti-financial crime solutions provider, which will speed up its shift to more software-as-a-service revenue.
We're maintaining our $500 fair value estimate for the narrow-moat drug manufacturer.
Astra’s vaccine looks potentially easier to transport with only mild temperature requirements as compared with the other vaccines.
The wide-moat asset manager plans to launch T. Rowe Price Investment Management.
Although the no-moat retailer performed better than expected in the third quarter, holiday concerns remain.
Nvidia reported impressive third-quarter results with revenue exceeding the high end of management’s guidance.
We plan to raise our fair value estimate for the no-moat company after a strong third quarter.
After reporting strong final data, we expect emergency authorization of Pfizer and BioNTech's vaccine by early December.
This is a critical step in our bullish thesis on Boeing, but it’s only the first in a series of steps in the company’s turnaround.
Its refocused international portfolio is a long-term benefit to the wide-moat company.
We expect to modestly increase its $200 fair value estimate.
We're maintaining Walgreens' narrow moat rating and $42 fair value estimate.
We believe the company has an opportunity to improve on existing mail-order prescription platforms.
Airbnb’s liquidity profile appears to be strong enough that solvency is a very low risk.
Unlike most periods, there were a few surprises in wide-moat Berkshire Hathaway's third-quarter 13-F filing, with the firm actually taking positions in four different healthcare firms--AbbVie, Merck, Bristol-Myers Squibb, and Pfizer.
Disney ended a challenging fiscal 2020 on a strong note. We maintain our wide moat and plan to modestly increase our $127 fair value estimate when we update our model.
With Cisco more positive about the demand environment ahead, shares increased over 7% after reporting. We are maintaining our $48 fair value estimate and believe shares are undervalued.